Bodine Journal

Article Title

Functional Antagonism Between Vorinostat and Temozolomide when Combined with Ionizing Radiation (IR) in Glioblastoma

Authors

Y. R. Lawrence, Thomas Jefferson University
Y. Liu, Thomas Jefferson University
B. Andersen, Thomas Jefferson UniversityFollow
X. Xia, Merck Research Laboratories
A. P. Dicker, Thomas Jefferson UniversityFollow
P. Wachsberger, Thomas Jefferson UniversityFollow

Abstract

Background: Glioblastoma is the most common primary adult brain tumor. Surgery followed by radiation therapy in combination with temozolomide (Tmz) produces a median survival of 14.6 months. Tmz is a DNA akylating agent that leads to the mispairing of guanine residues with thymine. An intact mismatch-repair mechanism (MMR) converts the mispaired thymine into a lethal double-strand DNA break. Vorinostat (SAHA), an HDAC inhibitor, has been shown to act as a radiosensitizer, possibly through inhibition of DNA repair. SAHA has successfully been combined with a number of cytotoxic agents. We hypothesized that SAHA would further potentiate the radiosensitizing properties of Tmz in glioblastoma.

American Association for Cancer Research (AACR) 101st Annual Meeting April 17-21, Washington, DC

Recommended Citation

Lawrence, Y. R.; Liu, Y.; Andersen, B.; Xia, X.; Dicker, A. P.; and Wachsberger, P. (2010) "Functional Antagonism Between Vorinostat and Temozolomide when Combined with Ionizing Radiation (IR) in Glioblastoma," Bodine Journal: Vol. 3: Iss. 1, Article 2.
DOI: https://doi.org/10.29046/TBJ.003.1.001
Available at: https://jdc.jefferson.edu/bodinejournal/vol3/iss1/2